MedTrace Logo

Co-trimoxazole as Maintenance Therapy for Melioidosis

NCT01420341 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 667

Last updated 2020-09-03

No results posted yet for this study

Summary

This is a randomised, open-labelled, controlled trial to compare the efficacy and effectiveness on relapse-free rate of 12-week versus 20-week oral eradication treatment of melioidosis. The study population includes 800 patients with culture-confirmed melioidosis whom 12 weeks of oral eradication therapy have been completed with or without intravenous intensive antibiotics. Patients will be randomised to either stop the eradication treatment or continue current oral treatment for 8 more weeks. The study aim to optimise the regimen used to treat melioidosis for better compliance and reducing unnecessary use of antibiotics.

Conditions

  • Melioidosis

Interventions

DRUG

Co-trimoxazole 12

Receive treatment with co-trimoxazole for 12 weeks.

DRUG

Co-trimoxazole 20

Receive treatment with co-trimoxazole for 20 weeks.

Sponsors & Collaborators

  • Khon Kaen University

    lead OTHER

Principal Investigators

  • Siriluck Anunnatsiri, MD · Khon Kaen Univerisity

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2019-06-21
Completion
2019-06-21

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01420341 on ClinicalTrials.gov